VISX and Summit dissolve Pillar Point partnership amid legal battles
This article was originally published in Clinica
The six-year old partnership to share patents in the laser eye surgery industry, which was claimed to have been instrumental in artificially raising prices in the US, is over. VISX and Summit Technology agreed last week to dissolve Pillar Point Partners, their vehicle formed in 1992 to license patents jointly and collect a $250 fee per eye for each procedure carried out in the US.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.